Shorts

Why ADCs Are Changing Breast Cancer Treatment

Can Targeted Therapies Redefine DLBCL Treatment?

Don’t Reinvent the Wheel: Peer Insights for Advanced Therapies

New Breast Cancer Trial Results: Omitting Surgery is Safe

Glossary Break: PFS vs OS

Glossary Break: All About Biomarkers

ASCO 2026: Brain Fog & Prostate Cancer Treatment

Dr Herzberg Talks Updates in KRAS-Mutant NSCLC

The Future of Breast Cancer Treatment: Escalation vs De-Escalation

Glossary Break: All About Liquid Biopsies

Navigating Financial Complexity of Advanced Therapies: A Role for Specialty Pharmacy

Coordinating Care When Every Minute Matters

Building the Foundation for Advanced Therapy Delivery in the Community

180 Advanced Therapies by 2030—Are Clinicians Ready?

BRIDGE: An Integrated Platform for Early-Onset Cancer Research and Care

National Study Affirms Value of Community Oncology

Bridging Oncology Silos to Improve Early-Onset Cancer Care

How Genome Sequencing Changed Cancer Research

Is Knowing Too Much About Your DNA Actually Dangerous?

From Generic to Personalized Cancer Care in Hours

A New Early-Onset Cancer Program Is Coordinating Fragmented Care

Why Early-Onset Cancer Cases Deserve Attention

Can Engineering Stem Cells to Prevent GVHD Save Health Systems Money?

60% of Early-Onset Cancers May Be Screenable

Does Weight Change How Cancer Cells Behave?

One Child Cured Equals Decades of Life Saved

A Powerful New Way to Measure Cancer Success

A Promising Breakthrough in Platinum-Resistant Ovarian Cancer Survival

IMNN-001: A Broader Approach to Immunotherapy

Cultivating A Culture of Clinical Trials in Pediatrics